Axovant Sciences Ltd. (NYSE:AXON) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Several other analysts have also recently commented on the company. Oppenheimer Holdings, Inc. increased their target price on Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a report on Monday, April 17th. CIBC increased their target price on Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a report on Tuesday, April 18th. Piper Jaffray Companies restated an “overweight” rating and set a $32.00 target price on shares of Axovant Sciences in a report on Wednesday, April 12th. Zacks Investment Research upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, March 9th. Finally, Jefferies Group LLC restated a “buy” rating and set a $31.00 target price on shares of Axovant Sciences in a report on Tuesday, April 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $27.68.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Shares of Axovant Sciences (AXON) traded down 0.54% during trading on Friday, hitting $23.87. 849,526 shares of the stock traded hands. The company’s market cap is $2.56 billion. Axovant Sciences has a 52 week low of $11.01 and a 52 week high of $25.18. The firm’s 50-day moving average price is $22.43 and its 200-day moving average price is $16.56.

Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Tuesday, June 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.02. On average, equities research analysts anticipate that Axovant Sciences will post ($2.11) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/23/axovant-sciences-ltd-axon-lifted-to-buy-at-bidaskclub.html.

In related news, insider David Hung bought 539,375 shares of Axovant Sciences stock in a transaction on Monday, April 17th. The shares were purchased at an average price of $18.54 per share, for a total transaction of $10,000,012.50. Following the completion of the acquisition, the insider now owns 539,375 shares in the company, valued at $10,000,012.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director W Anthony Vernon bought 53,937 shares of Axovant Sciences stock in a transaction on Monday, April 17th. The shares were bought at an average price of $18.54 per share, for a total transaction of $999,991.98. Following the acquisition, the director now owns 53,937 shares of the company’s stock, valued at approximately $999,991.98. The disclosure for this purchase can be found here. 3.10% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of AXON. Norges Bank bought a new position in shares of Axovant Sciences during the fourth quarter worth about $508,000. AQR Capital Management LLC bought a new position in shares of Axovant Sciences during the fourth quarter worth about $139,000. Woodstock Corp boosted its position in shares of Axovant Sciences by 55.0% in the first quarter. Woodstock Corp now owns 35,003 shares of the biotechnology company’s stock worth $523,000 after buying an additional 12,417 shares during the period. Nationwide Fund Advisors boosted its position in shares of Axovant Sciences by 70.9% in the first quarter. Nationwide Fund Advisors now owns 83,543 shares of the biotechnology company’s stock worth $1,248,000 after buying an additional 34,654 shares during the period. Finally, Primecap Management Co. CA boosted its position in shares of Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock worth $43,011,000 after buying an additional 2,159,428 shares during the period.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.